Literature DB >> 3496339

Sites of in vivo phosphorylation of the T cell tyrosine protein kinase in LSTRA cells and their alteration by tumor-promoting phorbol esters.

J E Casnellie.   

Abstract

The LSTRA cell line contains an elevated level of a tyrosine protein kinase of apparent molecular weight of 56,000 (pp56Tcell). Analysis of the tryptic fragments of this protein labeled in vivo with 32P shows that it contains four sites of tyrosine phosphorylation and one site of serine phosphorylation. Two of the sites of in vivo tyrosine phosphorylation are also labeled in vitro when membranes are incubated with [gamma-32P]ATP. One of the sites that is labeled in vivo and in vitro (site 1) is identical in sequence with the major site of tyrosine phosphorylation in the transforming protein of the Rous sarcoma virus. Analysis of the sites of in vivo phosphorylation in pp56Tcell from LSTRA cells treated with 4 beta-phorbol 12 beta-myristate 13 alpha-acetate (PMA) reveals that this agent induces at least four new sites of serine phosphorylation. Treatment with PMA also causes a selective reduction in the level of tyrosine phosphorylation in site 1. Thus PMA causes new sites of serine phosphorylation in pp56Tcell and reduces the amount of phosphate in one of the sites of tyrosine phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496339

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Association between B-lymphocyte membrane immunoglobulin and multiple members of the Src family of protein tyrosine kinases.

Authors:  M A Campbell; B M Sefton
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

2.  Purification and characterization of a higher-molecular-mass form of protein phosphotyrosine phosphatase (PTP 1B) from placental membranes.

Authors:  C J Pallen; D S Lai; H P Chia; I Boulet; P H Tong
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

3.  Neoplastic transformation induced by an activated lymphocyte-specific protein tyrosine kinase (pp56lck).

Authors:  J D Marth; J A Cooper; C S King; S F Ziegler; D A Tinker; R W Overell; E G Krebs; R M Perlmutter
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  Thrombin treatment induces rapid changes in tyrosine phosphorylation in platelets.

Authors:  A Golden; J S Brugge
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  Selective expression of alternative lck mRNAs in human malignant cell lines.

Authors:  O Sartor; F S Gregory; N S Templeton; S Pawar; R M Perlmutter; N Rosen
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

6.  Phosphorylation of Ser-42 and Ser-59 in the N-terminal region of the tyrosine kinase p56lck.

Authors:  D G Winkler; I Park; T Kim; N S Payne; C T Walsh; J L Strominger; J Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Translocation-independent activation of protein kinase C by platelet-activating factor, thrombin and prostacyclin. Lack of correlation with polyphosphoinositide hydrolysis in rabbit platelets.

Authors:  H Salari; V Duronio; S Howard; M Demos; S L Pelech
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

8.  Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase.

Authors:  T Mustelin; K M Coggeshall; A Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

9.  Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation.

Authors:  A Veillette; I D Horak; E M Horak; M A Bookman; J B Bolen
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

10.  The protein tyrosine kinase p56lck regulates cell adhesion mediated by CD4 and major histocompatibility complex class II proteins.

Authors:  M S Kinch; A Sanfridson; C Doyle
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.